Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 17 March 2026, 18:49 HKT/SGT
Share:
    

Source: Eisai
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation

TOKYO, Mar 17, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced the establishment of Eisai Global Capability Centre (EGCC) within Eisai Knowledge Centre, India, in Visakhapatnam (Vizag), Andhra Pradesh, India. The opening ceremony was held today, marking the commencement of its operation. The Centre serves as Eisai’s information technology hub.

(Standing from left to right) Muneo Takahashi, Consul General of Japan in Chennai (South India Jurisdiction); KeisukeNaito, Eisai COO and Chief Growth Officer; Yumiko Aoyagi, First Secretary, Embassy of Japan in India; VijayaKrishnan, IAS District Director, Anakapalli.)

The establishment of EGCC represents a core initiative of Eisai Group’s long-term IT strategy. By integrating external expertise and cutting-edge technologies, the EGCC insources the design and operation of internal information technology services. This, in turn, enables delivery of standardized high quality information technology services in a secure environment, strongly supporting Eisai Group’s global business operations. With the EGCC taking the lead in global IT functions, Eisai will transition its organizational structure, allowing regional IT functions to focus more on strategic business transformation aligning with their region-specific operations.

In its initial phase, the EGCC will focus primarily on standardizing global IT infrastructure operations. The Centre plans to gradually expand its scope to include cybersecurity, data & analytics, and operational applications, in response to business needs.

Eisai established “Eisai Knowledge Centre, India, in Andhra Pradesh in 2009. Since then the facility has served as a core operational hub for our global production and process research, while also contributing to employment creation in the local area. Andhra Pradesh is currently spearheading initiatives to establish a “New IT City” by designating Special Economic Zone (SEZ), attracting data centers and AI hubs, and aiming to create 300,000 IT jobs. By establishing the EGCC within the “Eisai Knowledge Centre, India”, we aim to recruit and nurture excellent global IT human resource who resonates with our “human health care (hhc)” concept. Through long-term employment and career development opportunities, we will contribute to the development of the local IT ecosystem and economic prosperity.

Media Inquiries:

Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Photographs of Inside and Outside of the Global Capability Center




Topic: Press release summary
Source: Eisai

Sectors: Enterprise IT, Datacenter & Cloud
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Mar 12, 2026 16:21 HKT/SGT
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
Mar 11, 2026 11:07 HKT/SGT
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
Mar 2, 2026 08:49 HKT/SGT
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Feb 16, 2026 13:03 HKT/SGT
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
Feb 10, 2026 12:34 HKT/SGT
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
Feb 6, 2026 10:31 HKT/SGT
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
Jan 26, 2026 10:37 HKT/SGT
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
Jan 21, 2026 15:44 HKT/SGT
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
Jan 13, 2026 08:50 HKT/SGT
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
Jan 6, 2026 09:43 HKT/SGT
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
More news >>
 News Alerts
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: